Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (1938)	4/17/1998 6:11:00 PM
From: Andrew Q. Viet	Read Replies (2) \| Respond to of 4676

Jubak's comments: As expected, Isis Pharmaceuticals (ISIP), a Jubak's Pick, has filed a new drug application with the Food & Drug Administration for fomivirsen. The company has asked the agency to approve the drug for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. The FDA is expected to rule, probably favorably, sometime in the second half of the year. Fomivirsen would be the first antisense drug to reach the market and that would be a powerful validation of Isis's antisense approach to drug design. My 12-month target price on Isis is $25. (Full disclosure: I own shares in Isis, purchased over the past 18 months, at approximately the current market price.)